Insulin resistance, adiponectin and adverse outcomes following elective cardiac surgery: A prospective follow-up study

Journal of Cardiothoracic Surgery

Volumn 5, Issue 1, 2010, Pages

  Mikkelsen, Martin M ^a   Hansen, Troels K ^a   Gjedsted, Jakob ^a   Andersen, Niels H ^a   Christensen, Thomas D ^a   Hjortdal, Vibeke E ^a   Johnsen, Søren P ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN;

AGED; ARTICLE; BLOOD; ELECTIVE SURGERY; FEMALE; FOLLOW UP; HEART DISEASE; HEART SURGERY; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADIPONECTIN; AGED; CARDIAC SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURGICAL PROCEDURES, ELECTIVE; TREATMENT OUTCOME;

EID: 78650016407     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-5-129     Document Type: Article

References (27)

1. Bagry HS, Raghavendran S, Carli F. Metabolic syndrome and insulin resistance: perioperative considerations. Anesthesiology 2008, 108:506-523. 10.1097/ALN.0b013e3181649314, 18292688.
2. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009, 73:608-614. 10.1253/circj.CJ-09-0057, 19261992.
3. Ioannou GN, Bryson CL, Boyko EJ. Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. J Diabetes Complications 2007, 21:363-370. 10.1016/j.jdiacomp.2006.07.005, 17967708.
4. Sato H, Carvalho G, Sato T, Lattermann R, Matsukawa T, Schricker T. The Association of Preoperative Glycemic Control, Intraoperative Insulin Sensitivity, and Outcomes after Cardiac Surgery. J Clin Endocrinol Metab 2010, 95(9):4338-44. Epub 2010 Jul 14, 10.1210/jc.2010-0135, 20631016.
5. Echahidi N, Pibarot P, Despres JP, Daigle JM, Mohty D, Voisine P, Baillot R, Mathieu P. Metabolic syndrome increases operative mortality in patients undergoing coronary artery bypass grafting surgery. J Am Coll Cardiol 2007, 50:843-851. 10.1016/j.jacc.2007.04.075, 17719470.
6. Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, Borger MA. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2005, 130:1144. 10.1016/j.jtcvs.2005.05.049, 16214532.
7. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002, 277:37487-37491. 10.1074/jbc.M206083200, 12138120.
8. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935. 10.1210/jc.86.5.1930, 11344187.
9. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006, 27:2300-2309. 10.1093/eurheartj/ehl153, 16864609.
10. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762. 10.1161/CIRCULATIONAHA.104.530972, 16157772.
11. Komai H, Shibata R, Juri M, Matsushita K, Ouchi N, Murohara T. Plasma adiponectin as a predictive factor of survival after a bypass operation for peripheral arterial disease. J Vasc Surg 2009, 50:95-99. 10.1016/j.jvs.2008.12.044, 19563957.
12. Choong CK, Sergeant P, Nashef SA, Smith JA, Bridgewater B. The EuroSCORE risk stratification system in the current era: how accurate is it and what should be done if it is inaccurate?. Eur J Cardiothorac Surg 2009, 35:59-61. 10.1016/j.ejcts.2008.10.009, 19027318.
13. de G, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol 2003, 56:221-229. 10.1016/S0895-4356(02)00585-1, 12725876.
14. Farrer M, Fulcher G, Albers CJ, Neil HA, Adams PC, Alberti KG. Patients undergoing coronary artery bypass graft surgery are at high risk of impaired glucose tolerance and diabetes mellitus during the first postoperative year. Metabolism 1995, 44:1016-1027. 10.1016/0026-0495(95)90099-3, 7637643.
15. Knapik P, Nadziakiewicz P, Urbanska E, Saucha W, Herdynska M, Zembala M. Cardiopulmonary bypass increases postoperative glycemia and insulin consumption after coronary surgery. Ann Thorac Surg 2009, 87:1859-1865. 10.1016/j.athoracsur.2009.02.066, 19463610.
16. Rapp-Kesek D, Stridsberg M, Andersson LG, Berne C, Karlsson T. Insulin resistance after cardiopulmonary bypass in the elderly patient. Scand Cardiovasc J 2007, 41:102-108. 10.1080/14017430601050355, 17454835.
17. Van den BG, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367. 10.1056/NEJMoa011300, 11794168.
18. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004, 109:1497-1502. 10.1161/01.CIR.0000121747.71054.79, 15006999.
19. Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O'Brien PC, Johnson MG, Williams AR, Cutshall SM, Mundy LM, Rizza RA, McMahon MM. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med 2007, 146:233-243.
20. Schnabel R, Messow CM, Lubos E, Espinola-Klein C, Rupprecht HJ, Bickel C, Sinning C, Tzikas S, Keller T, Genth-Zotz S, Lackner KJ, Munzel TF, Blankenberg S. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J 2008, 29:649-657. 10.1093/eurheartj/ehn009, 18263867.
21. Maiolino G, Cesari M, Sticchi D, Zanchetta M, Pedon L, Antezza K, Pessina AC, Rossi GP. Plasma adiponectin for prediction of cardiovascular events and mortality in high-risk patients. J Clin Endocrinol Metab 2008, 93:3333-3340. 10.1210/jc.2007-2405, 18697874.
22. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623-629. 10.1161/CIRCULATIONAHA.106.618918, 16894037.
23. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007, 165:164-174. 10.1093/aje/kwk001, 2642645, 17101706.
24. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009, 73:608-614. 10.1253/circj.CJ-09-0057, 19261992.
25. Joensen AM, Jensen MK, Overvad K, Dethlefsen C, Schmidt E, Rasmussen L, Tjonneland A, Johnsen S. Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry. J Clin Epidemiol 2008, 66:188-194.
26. Johnsen SP, Overvad K, Sorensen HT, Tjonneland A, Husted SE. Predictive value of stroke and transient ischemic attack discharge diagnoses in The Danish National Registry of Patients. J Clin Epidemiol 2002, 55:602-607. 10.1016/S0895-4356(02)00391-8, 12063102.
27. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495. 10.2337/diacare.27.6.1487, 15161807.